Abstract
Glioblastoma (GBM), a highly lethal brain tumor, has been comprehensively characterized at the molecular level with the identification of several potential treatment targets. Data concerning the Wnt pathway are relatively sparse, but apparently very important in defining several aspects of tumor biology. The Wnt ligands are involved in numerous basic biological processes including regulation of embryogenic development, cell fate determination, and organogenesis, but growing amount of data also support the roles of Wnt pathways in the formation of many tumors, including gliomas. Two main Wnt pathways are distinguished: the canonical (β-catenin) and non-canonical (planar cell polarity, Wnt/Ca2+) routes. Wnt signaling regulates glioma stem cells (GSCs), thereby defining invasive potential, recurrence, and treatment resistance of GBM. Some observations suggest that the Wnt pathways are differentially active in molecular subtypes of this tumor, thereby may also guide prognostication and novel therapeutic decisions. In this review, we highlight main elements and biological relevance of the Wnt pathways, primarily focusing on the pathogenesis and subtypes of GBM. Finally, we briefly summarize newer therapeutic strategies targeting networks of the Wnt signaling cascades and their molecular associates that appear to be marked contributors to GBM aggressiveness.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abla, A. A., Turner, J. D., & Sanai, N. (2012). FoxM1 is vital in the Wnt/β-catenin signaling pathogenesis of gliomas. World Neurosurgery, 77(5), 594–596. https://doi.org/10.1016/j.wneu.2012.03.001.
Anastas, J. N., & Moon, R. T. (2013). WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer, 13(1), 11. https://doi.org/10.1038/nrc3419.
Anson, M., Crain-Denoyelle, A. M., Baud, V., Chereau, F., Gougelet, A., Terris, B., et al. (2012). Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. The Journal of Clinical Investigation, 122(2), 586–599. https://doi.org/10.1172/JCI43937.
Asad, M., Wong, M. K., Tan, T. Z., Choolani, M., Low, J., Mori, S., et al. (2014). FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell Death & Disease, 5(7), e1346. https://doi.org/10.1038/cddis.2014.302.
Baarsma, H. A., Königshoff, M., & Gosens, R. (2013). The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacology & Therapeutics, 138(1), 66–83. https://doi.org/10.1016/j.pharmthera.2013.01.002.
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760.
Bikkavilli, R. K., Avasarala, S., Van Scoyk, M., Arcaroli, J., Brzezinski, C., Zhang, W., et al. (2015). Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene, 34(42), 5317.https://doi.org/10.1038/onc.2015.2.
Binda, E., Visioli, A., Giani, F., Trivieri, N., Palumbo, O., Restelli, S., et al. (2016). Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1693.
Borovski, T., Felipe De Sousa, E. M., Vermeulen, L., & Medema, J. P. (2011). Cancer stem cell niche: the place to be. Cancer Research, 71(3), 634–639. https://doi.org/10.1158/0008-5472.CAN-10-3220.
Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068. https://doi.org/10.1038/nature11903.
Carmon, K. S., & Loose, D. S. (2008). Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Molecular Cancer Research, 6(6), 1017–1028. https://doi.org/10.1158/1541-7786.MCR-08-0039.
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., Jones, D. L., & Wahl, G. M. (2006). Cancer stem cells–perspectiveson current status and future directions: AACR workshop on cancer stem cells. Cancer Research, 66, 9339–9344. https://doi.org/10.1158/0008-5472.CAN-06-3126.
Cui, D., Ren, J., Shi, J., Feng, L., Wang, K., Zeng, T., et al. (2016). R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling. The International Journal of Biochemistry & Cell Biology, 73, 72–81. https://doi.org/10.1016/j.biocel.2016.02.007.
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: models and concepts. Annual Review of Medicine, 58, 267–284. https://doi.org/10.1146/annurev.med.58.062105.204854.
Dang, L., Yen, K., & Attar, E. C. (2016). IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology, 27(4), 599–608. https://doi.org/10.1093/annonc/mdw013.
Darken, R. S., Scola, A. M., Rakeman, A. S., Das, G., Mlodzik, M., & Wilson, P. A. (2002). The planar polarity gene strabismus regulates convergent extension movements in Xenopus. The EMBO journal, 21(5), 976–985. https://doi.org/10.1093/emboj/21.5.976.
Daulat, A. M., & Borg, J. P. (2017). Wnt/planar cell polarity signaling: new opportunities for cancer treatment. Trends in Cancer, 3(2), 113–125. https://doi.org/10.1016/j.trecan.2017.01.001.
Debus, J., & Abdollahi, A. (2014). For the next trick: new discoveries in radiobiology applied to glioblastoma. In American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting (pp. e95–9). https://doi.org/10.14694/EdBook_AM.2014.34.e95.
Denysenko, T., Annovazzi, L., Cassoni, P., Melcarne, A., Mellai, M., & Schiffer, D. (2016). WNT/β-catenin signaling pathway and downstream modulators in low-and high-grade glioma. Cancer Genomics-Proteomics, 13(1), 31–45.
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., et al. (2018). Recurrent glioblastoma treated with recombinant poliovirus. New England Journal of Medicine, 379(2), 150–161. https://doi.org/10.1056/NEJMoa1716435.
Dijksterhuis, J. P., Arthofer, E., Marinescu, V. D., Nelander, S., Uhlén, M., Pontén, F., et al. (2015). High levels of WNT-5A in human glioma correlate with increased presence of tumor-associated microglia/monocytes. Experimental Cell Research, 339(2), 280–288. https://doi.org/10.1016/j.yexcr.2015.10.022.
Ellis, H. P., Greenslade, M., Powell, B., Spiteri, I., Sottoriva, A., & Kurian, K. M. (2015). Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence. Frontiers in oncology, 5, 251. https://doi.org/10.3389/fonc.2015.00251.
Eubelen, M., Bostaille, N., Cabochette, P., Gauquier, A., Tebabi, P., Dumitru, A. C., et al. (2018). A molecular mechanism for Wnt ligand-specific signaling. Science. https://doi.org/10.1126/science.aat1178.
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18(6), 553–567. https://doi.org/10.1016/j.ccr.2010.11.015.
Fontenot, E., Rossi, E., Mumper, R., Snyder, S., Siamakpour-Reihani, S., Ma, P., et al. (2013). A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Molecular Cancer Therapeutics, 12(5),685–695. https://doi.org/10.1158/1535-7163.MCT-12-1066.
Friedman, M. D., Jeevan, D. S., Tobias, M., Murali, R., & Jhanwar-Uniyal, M. (2013). Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncology Reports, 30(4), 1645–1650. https://doi.org/10.3892/or.2013.2625.
Fu, Y., Zheng, S., An, N., Athanasopoulos, T., Popplewell, L., Liang, A., et al. (2011). β-catenin as a potential key target for tumor suppression. International Journal of Cancer, 129(7), 1541–1551. https://doi.org/10.1002/ijc.26102.
Gao, X., & Jin, W. (2014). The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. Cancer Letters, 353(1), 25–31. https://doi.org/10.1016/j.canlet.2014.07.011.
Gao, X., McDonald, J. T., Naidu, M., Hahnfeldt, P., & Hlatky, L. (2014). A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics. Stem Cells International. https://doi.org/10.1155/2014/249309.
Gaspar, L. E., Fisher, B. J., Macdonald, D. R., Leber, D. V., Halperin, E. C., Schold, S. C., & Cairncross, J. G. (1992). Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. International Journal of Radiation Oncology Biology Physics, 24(1), 55–57.
Gil, J., Stembalska, A., Pesz, K. A., & Sąsiadek, M. M. (2008). Cancer stem cells: the theory and perspectives in cancer therapy. Journal of Applied Genetics, 49(2), 193–199. https://doi.org/10.1007/BF03195612.
Gong, A., & Huang, S. (2012). FoxM1 and Wnt/β-catenin signaling in glioma stem cells. Cancer Research, 72(22), 5658–5662. https://doi.org/10.1158/0008-5472.CAN-12-0953.
Gordon, M. D., & Nusse, R. (2006). Wnt signaling: multiple pathways, multiple receptors and multiple transcription factors. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.R600015200.
Götze, S., Wolter, M., Reifenberger, G., Müller, O., & Sievers, S. (2010). Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. International Journal of Cancer, 126(11), 2584–2593. https://doi.org/10.1002/ijc.24981.
Griveau, A., Seano, G., Shelton, S. J., Kupp, R., Jahangiri, A., Obernier, K., et al (2018). A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. Cancer Cell, 33(5), 874–889. https://doi.org/10.1016/j.ccell.2018.03.020.
He, B., You, L., Uematsu, K., Xu, Z., Lee, A. Y., Matsangou, M., et al. (2004). A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia, 6(1), 7–14. https://doi.org/10.15586/codon.glioblastoma.2017.ch2.
Hu, B., Wang, Q., Wang, Y. A., Hua, S., Sauvé, C. E. G., Ong, D., et al (2016). Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell, 167(5), 1281–1295. https://doi.org/10.1016/j.cell.2016.10.039.
Jackson, M., Hassiotou, F., & Nowak, A. (2014). Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis, 36(2), 177–185. https://doi.org/10.1093/carcin/bgu243.
Jin, X., Jeon, H. Y., Joo, K. M., Kim, J. K., Jin, J., Kim, S. H., et al. (2011). Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-10-1495.
Kahlert, U. D., Maciaczyk, D., Doostkam, S., Orr, B. A., Simons, B., Bogiel, T. al (2012). Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Letters, 325(1), 42–53. https://doi.org/10.1016/j.canlet.2012.05.024.
Kahlert, U. D., Suwala, A. K., Koch, K., Natsumeda, M., Orr, B. A., Hayashi, M., et al. (2015). Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. Journal of Neuropathology and Experimental Neurology, 74(9), 889–900. https://doi.org/10.1097/NEN.0000000000000227.
Kahn, M. (2014). Can we safely target the WNT pathway? Nature Reviews Drug Discovery, 13(7), 513–532. https://doi.org/10.1038/nrd4233.
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119(6), 1420–1428. https://doi.org/10.1172/JCI39104.
Kalovits, F., Tompa, M., Nagy, A., & Kalman, B. (2018). Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in GBM. Clinical Neuroscience, 71, 7–8. (In press).
Kamino, M., Kishida, M., Kibe, T., Ikoma, K., Iijima, M., Hirano, H., et al. (2011). Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Science, 102(3), 540–548. https://doi.org/10.1111/j.1349-7006.2010.01815.x.
Kaur, N., Chettiar, S., Rathod, S., Rath, P., Muzumdar, D., Shaikh, M. L., & Shiras, A. (2013). Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma. Molecular and Cellular Neuroscience, 54, 44–57. https://doi.org/10.1016/j.mcn.2013.01.001.
Kawano, Y., & Kypta, R. (2003). Secreted antagonists of the Wnt signalling pathway. Journal of Cell Science, 116(13), 2627–2634. https://doi.org/10.1242/jcs.00623.
Kikuchi, A., Yamamoto, H., Sato, A., & Matsumoto, S. (2011). New insights into the mechanism of Wnt signaling pathway activation. In International Review of Cell and Molecular Biology, 291, 21–71. https://doi.org/10.1016/B978-0-12-386035-4.00002-1.
Kim, J. H., Park, S. Y., Jun, Y., Kim, J. Y., & Nam, J. S. (2017). Roles of Wnt target genes in the journey of cancer stem cells. International Journal of Molecular Sciences, 18(8), 1604. https://doi.org/10.3390/ijms18081604.
Kim, Y. M., & Kahn, M. (2014). The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development. Research and Reports in Biochemistry, 4, 1–12.
Klaus, A., & Birchmeier, W. (2008). Wnt signalling and its impact on development and cancer. Nature Reviews Cancer, 8(5), 387. https://doi.org/10.1038/nrc2389.
Komiya, Y., & Habas, R. (2008). Wnt signal transduction pathways. Organogenesis, 4(2), 68–75.
Kouri, F. M., Hurley, L. A., Daniel, W. L., Day, E. S., Hua, Y., Hao, L., et al. (2015). miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes & Development, 29(7), 732–745. https://doi.org/10.1101/gad.257394.114.
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003). Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nature Neuroscience, 6(1), 21.
Lambiv, W. L., Vassallo, I., Delorenzi, M., Shay, T., Diserens, A. C., Misra, A., et al. (2011). The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-oncology, 13(7), 736–747. https://doi.org/10.1093/neuonc/nor036.
Lan, F., Yue, X., Han, L., Yuan, X., Shi, Z., Huang, K., et al. (2011). Antitumor effect of aspirin in glioblastoma cells by modulation of β-catenin/T-cell factor–mediated transcriptional activity. Journal of Neurosurgery, 115(4), 780–788. https://doi.org/10.3171/2011.5.JNS113.
Le Grand, F., Jones, A. E., Seale, V., Scimè, A., & Rudnicki, M. A. (2009). Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell, 4(6), 535–547. https://doi.org/10.1016/j.stem.2009.03.013.
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9(5), 391–403.
Lee, J. H., Lee, J. E., Kahng, J. Y., Kim, S. H., Park, J. S., Yoon, S. J., et al. (2018). Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature, 560(7717), 243–247. https://doi.org/10.1038/s41586-018-0389-3.
Lee, Y., Lee, J. K., Ahn, S. H., Lee, J., & Nam, D. H. (2016). WNT signaling in glioblastoma and therapeutic opportunities. Laboratory Investigation, 96(2), 137. https://doi.org/10.1038/labinvest.2015.140.
Lento, W., Congdon, K., Voermans, C., Kritzik, M., & Reya, T. (2013). Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harbor Perspectives in Biology, 5(2), a008011. https://doi.org/10.1101/cshperspect.a008011.
Lin, S. Y., Xia, W., Wang, J. C., Kwong, K. Y., Spohn, B., Wen, Y., et al. (2000). β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proceedings of the National Academy of Sciences, 97(8), 4262–4266.
Liu, X., Wang, L., Zhao, S., Ji, X., Luo, Y., & Ling, F. (2011). β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Medical Oncology, 28(2), 608–614. https://doi.org/10.1007/s12032-010-9476-5.
Liu, Z., Sun, B., Qi, L., Li, Y., Zhao, X., Zhang, D., & Zhang, Y. (2015). Dickkopf-1 expression is down-regulated during the colorectal adenoma–carcinoma sequence and correlates with reduced microvessel density and VEGF expression. Histopathology, 67(2), 158–166. https://doi.org/10.1111/his.12474.
Lo, H. W., Zhu, H., Cao, X., Aldrich, A., & Ali-Osman, F. (2009). A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Research, 69(17), 6790–6798. https://doi.org/10.1158/0008-5472.CAN-09-0886.
Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology, 20, 781–810.
Louis, D. N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820. https://doi.org/10.1007/s00401-016-1545-1.
Lu, P., Wang, Y., Liu, X., Wang, H., Zhang, X., Wang, K., et al. (2016). Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/β-catenin signaling. Medical Oncology, 33(7), 66. https://doi.org/10.1007/s12032-016-0778-0.
Ma, S., Jiang, B., Deng, W., Gu, Z. K., Wu, F. Z., Li, T., et al. (2015). D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget, 6(11), 8606. https://doi.org/10.18632/oncotarget.3330.
MacDonald, B. T., Tamai, K., & He, X. (2009). Wnt/β-catenin signaling: components, mechanisms, and diseases. Developmental Cell, 17(1), 9–26. https://doi.org/10.1016/j.devcel.2009.06.016.
Mansouri, A., Karamchandani, J., & Das, S. (2017). Molecular genetics of secondary glioblastoma. S. D. Vleeschouwer (Ed.), Glioblastoma (pp. 27–42). Codon Publications, Brisbane. ISBN: 978-0-9944381-2-6.
Matias, D., Dubois, L. G., Pontes, B., Rosário, L., Ferrer, V. P., Balça-Silva, J., et al. (2018). GBM-derived Wnt3a induces M2-like phenotype in microglial cells through Wnt/β-catenin signaling. Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1150-5.
Miller, J. R., Hocking, A. M., Brown, J. D., & Moon, R. T. (1999). Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca 2 + pathways. Oncogene, 18(55), 7860.
Morris, L. G., Kaufman, A. M., Gong, Y., Ramaswami, D., Walsh, L. A., Turcan, Ş, et al. (2013). Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 45(3), 253. https://doi.org/10.1038/ng.2538.
Nagy, Á., Garzuly, F., Padányi, G., Szűcs, I., Feldmann, Á., Murnyák, B., et al. (2017). Molecular subgroups of glioblastoma–an assessment by immunohistochemical markers. Pathology & Oncology Research. https://doi.org/10.1007/s12253-017-0311-6.
Nayak, L., Bhattacharyya, N. P., & De, R. K. (2016). Wnt signal transduction pathways: modules, development and evolution. BMC Systems Biology, 10(2), 44. https://doi.org/10.1186/s12918-016-0299-7.
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17(5), 510–522. https://doi.org/10.1016/j.ccr.2010.03.017.
Nusse, R., Brown, A., Papkoff, J., Scambler, P., Shackleford, G., McMahon, A., et al. (1991). A new nomenclature for int-1 and related genes: the Wnt gene family. Cell, 64(2), 231.
Nusse, R., & Varmus, H. E. (1982). Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31(1), 99–109. https://doi.org/10.1016/0092-8674(82)90409-3.
Ogawa, K., Yoshioka, Y., Isohashi, F., Seo, Y., Yoshida, K., & Yamazaki, H. (2013). Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Research, 33(3), 747–754.
Ohgaki, H., & Kleihues, P. (2012). The definition of primary and secondary glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-12-3002.
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321(5897), 1807–1812. https://doi.org/10.1126/science.1164382.
Paw, I., Carpenter, R. C., Watabe, K., Debinski, W., & Lo, H. W. (2015). Mechanisms regulating glioma invasion. Cancer Letters, 362(1), 1–7. https://doi.org/10.1016/j.canlet.2015.03.015.
Peifer, M., & Polakis, P. (2000). Wnt signaling in oncogenesis and embryogenesis–a look outside the nucleus. Science, 287(5458), 1606–1609.
Petropoulos, C., Guichet, P. O., Masliantsev, K., Wager, M., & Karayan-Tapon, L. (2018). Functional invadopodia formed in glioblastoma stem cells are important regulators of tumor angiogenesis. Oncotarget, 9(29), 20640–20657. https://doi.org/10.18632/oncotarget.25045.
Piao, Y., Liang, J., Holmes, L. S., Henry, V., Sulman, E. P., & de Groot, J. F. (2013). Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clinical Cancer Research, 19(16), 4392–4403. https://doi.org/10.1158/1078-0432.CCR-12-1557.
Polakis, P. (2012). Wnt signaling in cancer. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a008052.
Reis, M., Czupalla, C. J., Ziegler, N., Devraj, K., Zinke, J., Seidel, S., et al. (2012). Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20111580.
Rich, J. N. (2016). Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine, 95(Suppl 1), S2–S7. https://doi.org/10.1097/MD.0000000000004764.
Roarty, K., & Rosen, J. M. (2010). Wnt and mammary stem cells: hormones cannot fly wingless. Current Opinion in Pharmacology, 10(6), 643–649. https://doi.org/10.1016/j.coph.2010.07.004.
Safa, A. R., Saadatzadeh, M. R., Cohen-Gadol, A. A., Pollok, K. E., & Bijangi-Vishehsaraei, K. (2015). Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes & Diseases, 2(2), 152–163.
Sandberg, C. J., Altschuler, G., Jeong, J., Strømme, K. K., Stangeland, B., Murrell, W., et al. (2013). Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Experimental Cell Research, 319(14), 2230–2243. https://doi.org/10.1016/j.yexcr.2013.06.004.
Santiago, L., Daniels, G., Wang, D., Deng, F. M., & Lee, P. (2017). Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. American Journal of Cancer Research, 7(6), 1389–1406.
Segerman, A., Niklasson, M., Haglund, C., Bergström, T., Jarvius, M., Xie, Y., et al. (2016). Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition. Cell Reports, 17(11), 2994–3009. https://doi.org/10.1016/j.celrep.2016.11.056.
Sharma, R. P., & Chopra, V. L. (1976). Effect of the Wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. Developmental Biology, 48(2), 461–465. https://doi.org/10.1016/0012-1606(76)90108-1.
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2015). Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumor Biology, 36(2), 655–662. https://doi.org/10.1007/s13277-014-2644-z.
Shi, W., Bryan, M. S., Gilbert, M. R., Mehta, M. P., Blumenthal, D. T., Brown, P. D., et al. (2018). Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: A secondary analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International Journal of Radiation Oncology* Biology* Physics, 100(1), 38–44. https://doi.org/10.1016/j.ijrobp.2017.08.038.
Shu, W., Guttentag, S., Wang, Z., Andl, T., Ballard, P., Lu, M. M., et al. (2005). Wnt/β-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal–distal patterning in the lung. Developmental Biology, 283(1), 226–239. https://doi.org/10.1016/j.ydbio.2005.04.014.
Skoda, J., Hermanova, M., Loja, T., Nemec, P., Neradil, J., Karasek, P., & Veselska, R. (2016). Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. PloS one, 11(7), e0159255. https://doi.org/10.1371/journal.pone.0159255.
Steinke, F. C., & Xue, H. H. (2014). From inception to output, Tcf1 and Lef1 safeguard development of T cells and innate immune cells. Immunologic Research, 59(1–3), 45–55. https://doi.org/10.1007/s12026-014-8545-9.
Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996.
Suwala, A. K., Hanaford, A., Kahlert, U. D., & Maciaczyk, J. (2016). Clipping the wings of glioblastoma: Modulation of Wnt as a novel therapeutic strategy. Journal of Neuropathology & Experimental Neurology, 75(5), 388–396. https://doi.org/10.1093/jnen/nlw013.
Tada, M., Concha, M. L., & Heisenberg, C. P. (2002). Non-canonical Wnt signalling and regulation of gastrulation movements. Seminars in Cell & Developmental Biology, 13(3), 251–260.
Topol, L., Jiang, X., Choi, H., Garrett-Beal, L., Carolan, P. J., & Yang, Y. (2003). Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation. The Journal of Cell Biology, 162(5), 899–908.
Turcan, S., Fabius, A. W., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., et al. (2013). Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget, 4(10), 1729–1736.
Urakami, S., Shiina, H., Enokida, H., Hirata, H., Kawamoto, K., Kawakami, T., et al. (2006). Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clinical Cancer Research, 12(23), 6989–6997. https://doi.org/10.1158/1078-0432.CCR-06-1194.
Utsuki, S., Sato, Y., Oka, H., Tsuchiya, B., Suzuki, S., & Fujii, K. (2002). Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. Journal of Neuro-oncology, 57(3), 187–192.
Valenta, T., Hausmann, G., & Basler, K. (2012). The many faces and functions of β-catenin. The EMBO Journal, 31(12), 2714–2736. https://doi.org/10.1038/emboj.2012.
Vassallo, I., Zinn, P., Lai, M., Rajakannu, P., Hamou, M. F., & Hegi, M. E. (2016). WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene, 35(1), 12. https://doi.org/10.1038/onc.2015.61.
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020.
Visani, M., De Biase, D., Marucci, G., Cerasoli, S., Nigrisoli, E., Bacchi Reggiani, M. L., et al. (2014). Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III. Molecular Oncology, 8(2), 417–430. https://doi.org/10.1016/j.molonc.2013.12.010.
Voloshanenko, O., Erdmann, G., Dubash, T. D., Augustin, I., Metzig, M., Moffa, G., et al. (2013). Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature Communications, 4, 2610. https://doi.org/10.1038/ncomms3610.
Wang, P. F., Liu, N., Song, H. W., Yao, K., Jiang, T., Li, S. W., et al. (2016). IDH-1R132H mutation status in diffuse glioma patients: implications for classification. Oncotarget, 7(21), 31393. https://doi.org/10.18632/oncotarget.8918.
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., et al. (2017). Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell, 32(1), 42–56. https://doi.org/10.1016/j.ccell.2017.12.012.
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., et al. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet Oncology, 18(10), 1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X.
Willert, K., & Nusse, R. (2012). Wnt proteins. Cold Spring Harbor Perspectives in Biology, 4(9), a007864.
Wu, F., Cheng, G., Yao, Y., Kogiso, M., Jiang, H., Li, X. N., & Song, Y. (2018). Inhibition of mutated isocitrate dehydrogenase 1 in cancer. Medicinal Chemistry (Shariqah (United Arab Emirates)). https://doi.org/10.2174/1573406414666180524093659.
Xiang, S., Gu, H., Jin, L., Thorne, R. F., Zhang, X. D., & Wu, M. (2018). LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect. Proceedings of the National Academy of Sciences, 115(7), E1465–E1474. https://doi.org/10.1073/pnas.1711257115.
Xie, Q., Mittal, S., & Berens, M. E. (2014). Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro-oncology, 16(12), 1575–1584. https://doi.org/10.1093/neuonc/nou147.
Yang, J., & Weinberg, R. A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell, 14(6), 818–829. https://doi.org/10.1016/j.devcel.2008.05.009.
Yang, L., Wu, X., Wang, Y., Zhang, K., Wu, J., Yuan, Y. C., et al. (2011). FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene, 30(43), 4437. https://doi.org/10.1038/onc.2011.145.
Yao, Q., Cai, G., Yu, Q., Shen, J., Gu, Z., Chen, J., et al. (2018). IDH1 mutation diminishes aggressive phenotype in glioma stem cells. International Journal of Oncology, 52(1), 270–278. https://doi.org/10.3892/ijo.2017.4186.
Yao, Y. L., Ma, J., Wang, P., Xue, Y. X., Li, Z., Zhao, L. N., et al. (2015). miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. CNS Neuroscience & Therapeutics, 21(1), 40–51. https://doi.org/10.1111/cns.12321.
Yeung, J., Esposito, M. T., Gandillet, A., Zeisig, B. B., Griessinger, E., Bonnet, D., & So, C. W. E. (2010). β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell, 18(6), 606–618. https://doi.org/10.1016/j.ccr.2010.10.032.
Zhang, H., Qi, Y., Geng, D., Shi, Y., Wang, X., Yu, R., & Zhou, X. (2018). Expression profile and clinical significance of Wnt signaling in human gliomas. Oncology Letters, 15(1), 610–617. https://doi.org/10.3892/ol.2017.7315.
Zhang, K., Zhu, S., Liu, Y., Dong, X., Shi, Z., Zhang, A., et al. (2015). ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity. Cancer Letters, 357(1), 404–411. https://doi.org/10.1016/j.canlet.2014.11.047.
Zhang, N., Wei, P., Gong, A., Chiu, W. T., Lee, H. T., Colman, H., et al (2011). FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell, 20(4), 427–442. https://doi.org/10.1016/j.ccr.2011.08.016.
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V., et al. (2010). PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell, 17(5), 497–509. https://doi.org/10.1016/j.ccr.2010.03.020.
Acknowledgements
The authors are grateful for the support provided by the Graduate School of Clinical Neurosciences, University of Pecs, and the Markusovszky University Teaching Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tompa, M., Kalovits, F., Nagy, A. et al. Contribution of the Wnt Pathway to Defining Biology of Glioblastoma. Neuromol Med 20, 437–451 (2018). https://doi.org/10.1007/s12017-018-8514-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-018-8514-x